The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Northern District of California on behalf of shareholders of Twist Bioscience Corporation who purchased common stock between December 13, 2019, and November 14, 2022.
1) as alleged in the November 15, 2022 report by Scorpion Capital, defendants overstated the commercial viability of Twist’s synthetic DNA manufacturing technology; and 2) at the same time, defendants were engaging in accounting fraud and using unsustainable pricing to inflate the Company’s true financial condition and prospects.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until February 10, 2023 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
